Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab, Lenvatinib, and VP-16 in Platinum-Resistant Recurrent Ovarian Cancer
NCT05422183Phase 2Unknown
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Zhongda Hospital, Southeast University. Status: unknown.
02
Drugs
envafolimab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05422183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422183.